argenx Stock Dips as Goldman Raises Price Target

argenx stock fell by 1.79% on October 2, 2026, as Goldman Sachs raised its 12-month price target for the biotechnology company.

The move occurred after argenx reported a strong Q2 earnings report, with revenue exceeding analyst estimates at $1.54 billion and adjusted earnings per share of $7.32 surpassing the consensus by $1.46.

Goldman Sachs' price target increase to EUR 982 from EUR 973, as well as its Buy rating, adds a forward checkpoint for argenx stock ahead of its next major date: the October 22 quarterly report.